{"id":59619,"date":"2026-03-16T16:19:45","date_gmt":"2026-03-16T08:19:45","guid":{"rendered":"https:\/\/flcube.com\/?p=59619"},"modified":"2026-03-16T16:19:46","modified_gmt":"2026-03-16T08:19:46","slug":"3sbio-wins-nmpa-approval-for-eltrombopag-generic-tpo-ra-copycat-targets-novartis-revolade-in-china-itp-saa-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59619","title":{"rendered":"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis’ Revolade in China ITP\/SAA Market"},"content":{"rendered":"\n

3SBio Inc.<\/strong> (HKG: 1530<\/a>) announced NMPA marketing approval<\/strong> for its generic version of Novartis’ Revolade (eltrombopag olamine)<\/strong>, an oral thrombopoietin receptor agonist (TPO-RA)<\/strong> for chronic immune thrombocytopenia (ITP)<\/strong> and severe aplastic anemia (SAA)<\/strong>. The approval adds 3SBio<\/strong> to a crowded field of Chinese eltrombopag copycats<\/strong>, including Qilu Pharmaceutical, Kelun Pharmaceutical, and Chia Tai Tianqing<\/strong>, intensifying price competition<\/strong> in the growing thrombocytopenia market<\/strong> as the originator’s China exclusivity<\/strong> (market entry 2017) expires<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>National Medical Products Administration (NMPA)<\/td><\/tr>
Approval Type<\/strong><\/td>Generic marketing authorization<\/td><\/tr>
Product<\/strong><\/td>Eltrombopag olamine tablets (generic)<\/td><\/tr>
Reference Product<\/strong><\/td>Revolade (Novartis) \u2013 first approved U.S. 2008; China 2017<\/td><\/tr>
Drug Class<\/strong><\/td>Oral, small-molecule thrombopoietin receptor agonist (TPO-RA)<\/td><\/tr>
Indications<\/strong><\/td>\u2022 Chronic ITP (adults and pediatrics \u22656 years) \u2013 post-corticosteroid\/immunoglobulin failure
\u2022 Severe aplastic anemia (SAA) \u2013 post-immunosuppressive therapy failure<\/td><\/tr>
Developer<\/strong><\/td>3SBio Inc. (HKG: 1530)<\/td><\/tr>
Competitive Field<\/strong><\/td>Qilu Pharmaceutical, Kelun Pharmaceutical, Chia Tai Tianqing (also approved)<\/td><\/tr>
Approval Date<\/strong><\/td>16\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>Eltrombopag Olamine Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Thrombopoietin receptor (TPO-R) agonist; stimulates megakaryocyte proliferation and platelet production<\/td><\/tr>
Route<\/strong><\/td>Oral administration (daily)<\/td><\/tr>
Clinical Outcomes<\/strong><\/td>Increases platelet counts; reduces bleeding risk; improves quality of life<\/td><\/tr>
Originator Status<\/strong><\/td>Novartis Revolade \u2013 global blockbuster; ~$1.5 billion annual sales peak<\/td><\/tr>
Generic Advantage<\/strong><\/td>Lower cost vs. originator; improved access in price-sensitive China market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Dynamics<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
ITP Market Size<\/strong><\/td>China: ~100,000 diagnosed chronic ITP patients; growing diagnosis rates<\/td><\/tr>
SAA Market<\/strong><\/td>~5,000 annual new SAA cases; high unmet need; eltrombopag standard of care post-IST failure<\/td><\/tr>
Originator Exclusivity<\/strong><\/td>Novartis Revolade China launch 2017; ~8-9 years market exclusivity; now facing generic wave<\/td><\/tr>
Generic Competition<\/strong><\/td>4+ Chinese companies approved; price erosion 50-70% anticipated; volume-based procurement likely<\/td><\/tr>
3SBio Positioning<\/strong><\/td>Established biologics manufacturer (EPIAO, SEPO); adds small molecule oral portfolio; hospital formulary leverage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Landscape<\/h2>\n\n\n\n
Company<\/th>Product<\/th>Status<\/th>Market Position<\/th><\/tr><\/thead>
Novartis<\/strong><\/td>Revolade (originator eltrombopag)<\/td>Marketed since 2017<\/td>Brand premium; physician loyalty; pediatric experience<\/td><\/tr>
Qilu Pharmaceutical<\/strong><\/td>Generic eltrombopag<\/td>Approved<\/td>First-mover generic advantage<\/td><\/tr>
Kelun Pharmaceutical<\/strong><\/td>Generic eltrombopag<\/td>Approved<\/td>Manufacturing scale; distribution strength<\/td><\/tr>
Chia Tai Tianqing<\/strong><\/td>Generic eltrombopag<\/td>Approved<\/td>Oncology portfolio synergy<\/td><\/tr>
3SBio<\/strong><\/td>Generic eltrombopag<\/strong><\/td>Approved (March 2026)<\/strong><\/td>Biologics expertise; renal\/hematology franchise fit<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Outlook<\/h2>\n\n\n\n
Priority<\/th>Timeline<\/th>Strategy<\/th><\/tr><\/thead>
NRDL Negotiation<\/strong><\/td>2026-2027<\/td>National reimbursement list inclusion critical for volume; price competition intensifies<\/td><\/tr>
Volume-Based Procurement<\/strong><\/td>2027+<\/td>National tender likely; winner-take-most market dynamics<\/td><\/tr>
Hospital Formulary<\/strong><\/td>2026+<\/td>Leverage 3SBio’s existing hematology\/oncology relationships<\/td><\/tr>
Indication Expansion<\/strong><\/td>Ongoing<\/td>Pediatric ITP (\u22656 years) and SAA marketing; real-world evidence generation<\/td><\/tr>
Global Potential<\/strong><\/td>2027+<\/td>Emerging market export; WHO prequalification for ITP\/SAA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding pricing dynamics, market share capture, and competitive positioning for 3SBio’s eltrombopag generic. Actual results may differ due to volume-based procurement outcomes, physician prescribing patterns, and originator defense strategies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis’ Revolade…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[116,1061,140,15],"class_list":["post-59619","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-3sbio","tag-hkg-1530","tag-novartis","tag-product-approvals"],"yoast_head":"\n3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis' Revolade in China ITP\/SAA Market - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis' Revolade (eltrombopag olamine), an oral thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The approval adds 3SBio to a crowded field of Chinese eltrombopag copycats, including Qilu Pharmaceutical, Kelun Pharmaceutical, and Chia Tai Tianqing, intensifying price competition in the growing thrombocytopenia market as the originator's China exclusivity (market entry 2017) expires.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59619\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis' Revolade in China ITP\/SAA Market\" \/>\n<meta property=\"og:description\" content=\"3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis' Revolade (eltrombopag olamine), an oral thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The approval adds 3SBio to a crowded field of Chinese eltrombopag copycats, including Qilu Pharmaceutical, Kelun Pharmaceutical, and Chia Tai Tianqing, intensifying price competition in the growing thrombocytopenia market as the originator's China exclusivity (market entry 2017) expires.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59619\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T08:19:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-16T08:19:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59619#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59619\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis’ Revolade in China ITP\\\/SAA Market\",\"datePublished\":\"2026-03-16T08:19:45+00:00\",\"dateModified\":\"2026-03-16T08:19:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59619\"},\"wordCount\":446,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"3SBio\",\"HKG: 1530\",\"Novartis\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59619#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59619\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59619\",\"name\":\"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis' Revolade in China ITP\\\/SAA Market - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-16T08:19:45+00:00\",\"dateModified\":\"2026-03-16T08:19:46+00:00\",\"description\":\"3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis' Revolade (eltrombopag olamine), an oral thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The approval adds 3SBio to a crowded field of Chinese eltrombopag copycats, including Qilu Pharmaceutical, Kelun Pharmaceutical, and Chia Tai Tianqing, intensifying price competition in the growing thrombocytopenia market as the originator's China exclusivity (market entry 2017) expires.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59619#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59619\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59619#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis’ Revolade in China ITP\\\/SAA Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis' Revolade in China ITP\/SAA Market - Insight, China's Pharmaceutical Industry","description":"3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis' Revolade (eltrombopag olamine), an oral thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The approval adds 3SBio to a crowded field of Chinese eltrombopag copycats, including Qilu Pharmaceutical, Kelun Pharmaceutical, and Chia Tai Tianqing, intensifying price competition in the growing thrombocytopenia market as the originator's China exclusivity (market entry 2017) expires.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59619","og_locale":"en_US","og_type":"article","og_title":"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis' Revolade in China ITP\/SAA Market","og_description":"3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis' Revolade (eltrombopag olamine), an oral thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The approval adds 3SBio to a crowded field of Chinese eltrombopag copycats, including Qilu Pharmaceutical, Kelun Pharmaceutical, and Chia Tai Tianqing, intensifying price competition in the growing thrombocytopenia market as the originator's China exclusivity (market entry 2017) expires.","og_url":"https:\/\/flcube.com\/?p=59619","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-16T08:19:45+00:00","article_modified_time":"2026-03-16T08:19:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59619#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59619"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis’ Revolade in China ITP\/SAA Market","datePublished":"2026-03-16T08:19:45+00:00","dateModified":"2026-03-16T08:19:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59619"},"wordCount":446,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["3SBio","HKG: 1530","Novartis","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59619#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59619","url":"https:\/\/flcube.com\/?p=59619","name":"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis' Revolade in China ITP\/SAA Market - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-16T08:19:45+00:00","dateModified":"2026-03-16T08:19:46+00:00","description":"3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis' Revolade (eltrombopag olamine), an oral thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The approval adds 3SBio to a crowded field of Chinese eltrombopag copycats, including Qilu Pharmaceutical, Kelun Pharmaceutical, and Chia Tai Tianqing, intensifying price competition in the growing thrombocytopenia market as the originator's China exclusivity (market entry 2017) expires.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59619#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59619"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59619#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"3SBio Wins NMPA Approval for Eltrombopag Generic \u2013 TPO-RA Copycat Targets Novartis’ Revolade in China ITP\/SAA Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59619"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59619\/revisions"}],"predecessor-version":[{"id":59620,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59619\/revisions\/59620"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}